Petros Grivas, MD, PhD

Articles

Role of Chemoimmunotherapy in Frontline Treatment of mUC

March 19, 2021

Petros Grivas, MD, PhD, discusses the role of concurrent immune checkpoint inhibition plus chemotherapy in first-line metastatic urothelial carcinoma and comments on the ongoing phase 3 NILE, CheckMate 901, and EV-3O2 studies.

Approaching ICI Maintenance Therapy in Urothelial Carcinoma

March 19, 2021

Considerations for approaching avelumab switch maintenance after frontline chemotherapy response and data from the 2021 ASCO GU Virtual Symposium on ICI maintenance therapy in metastatic urothelial carcinoma.